Related Experiment Video
Updated: May 27, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Comparison of inhibitory efficacy of short interfering RNAs targeting different genes on Measles virus replication
Junyan Shi1, Meilian Wang, Jian Wang
1The Department of Microbiology and Parasitology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, P.R. China. junyanshi112@sina.com
Abstract:
RNA interference (RNAi)-based short interfering RNAs (siRNAs) targeting the viral genes and the host cellular genes have been used to suppress Measles virus (MV) replication in vitro. In order to select suitable target genes and highly effective target sites for developing effective RNAi-mediated anti-MV therapy, in this study, nine short hairpin RNA (shRNA) expression vectors, which expressed siRNAs targeting the host celluar Rab9 GTPase gene, the viral large protein (L) gene and nucleoprotein (N) gene, respectively, were constructed and used to compare their ability to inhibit MV replication in Vero-E6 cells. The results showed that nine siRNAs targeting different genes exhibited different inhibitory efficacy on MV replication in vitro (about 23-94%), which could last at least 168 h post-infection. Of the nine siRNAs, R2, L1 and N2 more effectively decreased MV replication by over 90%. Furthermore, inhibitory efficacy on MV replication were increased and reached almost 100% when cells were transfected with pR2, pL1 and pN2 together. These results emphasis the importance of selecting suitable siRNA target sites for developing siRNAs-based drug therapy for MV, and demonstrate the potential of combination of siRNAs targeting different genes as a therapeutic approach to treat MV infection.
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibitors of Virion Maturation and Assembly

